Artificial intelligence in histopathology: enhancing cancer research and clinical oncology
Artificial intelligence (AI) methods have multiplied our capabilities to extract quantitative
information from digital histopathology images. AI is expected to reduce workload for human …
information from digital histopathology images. AI is expected to reduce workload for human …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Pembrolizumab plus chemotherapy in advanced endometrial cancer
RN Eskander, MW Sill, L Beffa, RG Moore… - … England Journal of …, 2023 - Mass Medical Soc
Background Standard first-line chemotherapy for endometrial cancer is paclitaxel plus
carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear …
carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear …
FIGO staging of endometrial cancer: 2023
JS Berek, X Matias‐Guiu, C Creutzberg… - … of Gynecology & …, 2023 - Wiley Online Library
Introduction Many advances in the understanding of the pathologic and molecular features
of endometrial cancer have occurred since the FIGO staging was last updated in 2009 …
of endometrial cancer have occurred since the FIGO staging was last updated in 2009 …
[PDF][PDF] Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A Oaknin, TJ Bosse, CL Creutzberg, G Giornelli… - Annals of oncology, 2022 - Elsevier
Highlights•This ESMO Clinical Practice Guideline provides key recommendations for
managing endometrial cancer.•The guideline covers clinical and pathological diagnosis …
managing endometrial cancer.•The guideline covers clinical and pathological diagnosis …
[HTML][HTML] Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …
[HTML][HTML] Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) …
Background Dostarlimab is a humanized monoclonal antibody that binds with high affinity to
PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We report interim data from …
PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We report interim data from …
Cancer of the corpus uteri: 2021 update
Endometrial cancer is the most common gynecological malignancy in high‐and middle‐
income countries. Although the overall prognosis is relatively good, high‐grade endometrial …
income countries. Although the overall prognosis is relatively good, high‐grade endometrial …
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy
A León-Castillo, SM De Boer, ME Powell… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
DNA methylation profiling: an emerging paradigm for cancer diagnosis
A Papanicolau-Sengos, K Aldape - Annual Review of Pathology …, 2022 - annualreviews.org
Histomorphology has been a mainstay of cancer diagnosis in anatomic pathology for many
years. DNA methylation profiling is an additional emerging tool that will serve as an adjunct …
years. DNA methylation profiling is an additional emerging tool that will serve as an adjunct …